Skip Navigation

Randomized Phase III Trial of Mfolfirnox +/- Nivolumab Vs. Folfox +/- Nivolumab for First-line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT05677490

Study #:
STUDY00150244

Start Date:
Jun 15, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05677490

View Complete Trial Details & Eligibility at ClinicalTrials.gov